Dydrogesterone, estradiol
Sold as Femoston, Femoston-conti, Femoston conti
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 4
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Abbott Laboratories S.A. (Pty) Ltd | Femoston, Femoston-conti, Femoston conti | 0,5 mg/ 2,5 mg, 1/10, 2/10 | 300256, 360329, 360330, 470947 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Femoston 2/10 EACH BLISTER PACK CONTAINS :DYDROGESTERONE 10,0 mg, Estradiol 2,0 mg | 2/10 | 30025630/21.8.2/0256 | Registered | Not determined | None |
| Femoston 1/10 EACH TABLET CONTAINS :DYDROGESTERONE A 10,0 mg, ESTRADIOL A 1,0 mg | 1/10 | 36032936/21.8.2/0329 | Registered | Not determined | None |
| Femoston-conti EACH TABLET CONTAINS : DYDROGESTERONE 5,0 mg, ESTRADIOL 1,0 mg | Not listed | 36033036/21.8.2/0330 | Registered | Not determined | None |
| Femoston conti 0,5 mg/ 2,5 MG EACH TABLET CONTAINS :ESTRADIOL HEMIHYDRATE EQUIVALENT TO ESTRADIOL 0,5 mg; DYDROGESTERONE 2,5 mg | 0,5 mg/ 2,5 mg | 47094747/21.8.2/0947 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Dydrogesterone
Consolidated Schedules 06 July 2026, line 6143
S4: Estradiol
- when intended for hormone replacement therapy;
- except when intended for human vaginal use; (S2)
- except when intended for oral contraception. (S3)
Consolidated Schedules 06 July 2026, lines 6246 to 6251
S3: Estradiol
- when intended for oral contraception;
- except when intended for human vaginal use; (S2)
- except when intended for hormone replacement therapy. (S4)
Consolidated Schedules 06 July 2026, lines 3514 to 3524
S2: Estradiol
- when intended for human vaginal use;
- except when intended for oral contraception; (S3)
- except when intended for hormone replacement therapy. (S4)
Consolidated Schedules 06 July 2026, lines 1927 to 1933
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.